CY1122134T1 - Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας - Google Patents

Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας

Info

Publication number
CY1122134T1
CY1122134T1 CY20191100855T CY191100855T CY1122134T1 CY 1122134 T1 CY1122134 T1 CY 1122134T1 CY 20191100855 T CY20191100855 T CY 20191100855T CY 191100855 T CY191100855 T CY 191100855T CY 1122134 T1 CY1122134 T1 CY 1122134T1
Authority
CY
Cyprus
Prior art keywords
composition
therapeutic treatment
gastrointestinal dysfunction
patient
ghrelin
Prior art date
Application number
CY20191100855T
Other languages
English (en)
Inventor
Rakesh Datta
Zheng Xin Dong
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Publication of CY1122134T1 publication Critical patent/CY1122134T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Η παρούσα εφεύρεση αφορά σε μια μέθοδο θεραπευτικής αντιμετώπισης μιας παροδικής διαταραχής της κινητικότητας του γαστρεντερικού συστήματος ως αποτέλεσμα μετεγχειρητικού ειλεού σε έναν ασθενή, όπου η εν λόγω μέθοδος περιλαμβάνει τη βαθμίδα της χορήγησης μιας θεραπευτικά αποτελεσματικής ποσότητας ενός ανάλογου πεπτιδυλίου της γκρελίνης στον εν λόγω ασθενή.
CY20191100855T 2005-09-29 2019-08-08 Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας CY1122134T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72191605P 2005-09-29 2005-09-29
PCT/US2006/038027 WO2007041278A2 (en) 2005-09-29 2006-09-28 Composition and methods for stimulating gastrointestinal motility

Publications (1)

Publication Number Publication Date
CY1122134T1 true CY1122134T1 (el) 2020-11-25

Family

ID=37906731

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100855T CY1122134T1 (el) 2005-09-29 2019-08-08 Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας

Country Status (14)

Country Link
US (6) US7932231B2 (el)
EP (2) EP1937262B1 (el)
JP (4) JP5230430B2 (el)
CN (3) CN103251933A (el)
CA (1) CA2625447C (el)
CY (1) CY1122134T1 (el)
DK (1) DK1937262T3 (el)
ES (1) ES2740108T3 (el)
HU (1) HUE044391T2 (el)
PL (1) PL1937262T3 (el)
PT (1) PT1937262T (el)
RU (2) RU2566708C2 (el)
SI (1) SI1937262T1 (el)
WO (1) WO2007041278A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
ES2474643T3 (es) * 2005-09-28 2014-07-09 Ipsen Pharma Análogos de grelina
PT1937262T (pt) * 2005-09-29 2019-08-21 Ipsen Pharma Sas Composição para utilização no tratamento de dismotilidade gastrointestinal
EP2118080B1 (en) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
AU2013201451B2 (en) * 2007-08-08 2015-07-30 Ipsen Pharma S.A.S. Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
WO2009082426A1 (en) * 2007-12-21 2009-07-02 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
CA2739418A1 (en) 2008-10-03 2010-04-08 The Johns Hopkins University Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes
WO2011115871A1 (en) * 2010-03-15 2011-09-22 Ipsen Pharma S.A.S. Pharmaceutical compositions of growth hormone secretagogue receptor ligands
RU2475757C1 (ru) * 2012-02-02 2013-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования тяжести течения послеоперационного периода у больных калькулезным холециститом
JP2015510505A (ja) * 2012-02-03 2015-04-09 ジーランド ファーマ アクティーゼルスカブ グレリン類似体
JP6295247B2 (ja) * 2013-03-25 2018-03-14 ゼリア新薬工業株式会社 食後期の胃運動亢進剤
CA2978216A1 (en) 2014-03-04 2015-09-11 Motus Therapeutics, Inc. Process for the liquid phase synthesis of h-inp-(d)bal-(d)trp-phe-apc-nh2, and pharmaceutically acceptable salts thereof
CN113072617B (zh) * 2021-03-30 2023-08-08 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用
CN114805487B (zh) * 2022-06-07 2024-03-12 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1993A (en) 1841-02-23 Elbridge G Matthews Manufacture of plows
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5362756A (en) 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
US5264565A (en) 1991-01-22 1993-11-23 Affymax Technologies, N.V. Nucleic acid encoding the D2 /Ml chimeric receptor
PL174772B1 (pl) 1993-01-06 1998-09-30 Kinerton Ltd Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy
JPH10507934A (ja) 1995-07-26 1998-08-04 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 代謝指向型グルタミン酸受容体に活性を示す化合物を同定するためのキメラ受容体および方法、ならびに神経学的障害および疾患の治療におけるそのような化合物の使用
AU2405697A (en) 1996-04-25 1997-11-12 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ATE449174T1 (de) 1999-07-23 2009-12-15 Kenji Kangawa Neue peptide
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
AU2001283938A1 (en) 2000-07-24 2002-02-05 Ardana Bioscience Limited Ghrelin antagonists
ATE552031T1 (de) 2001-12-18 2012-04-15 Alize Pharma Sas Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
PT1578778E (pt) * 2002-07-23 2011-03-07 Ipsen Pharma Análogos de grelina
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
MXPA05008097A (es) 2003-01-28 2006-02-08 Microbia Inc Metodos y composiciones para el tratamiento de desordenes gastrointestinales.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US6911430B2 (en) 2003-10-01 2005-06-28 Vipogen, Llc Compositions and methods for treating ileus
EP1682136A4 (en) 2003-11-04 2009-06-03 Elixir Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND CORRESPONDING USES THEREOF
KR20130048793A (ko) * 2004-08-12 2013-05-10 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을 촉진하는 방법
AU2005277389A1 (en) * 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
WO2007014258A2 (en) * 2005-07-22 2007-02-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Growth hormone secretagogues
ES2474643T3 (es) * 2005-09-28 2014-07-09 Ipsen Pharma Análogos de grelina
PT1937262T (pt) * 2005-09-29 2019-08-21 Ipsen Pharma Sas Composição para utilização no tratamento de dismotilidade gastrointestinal
EP2012809B1 (en) * 2006-03-10 2013-05-22 Ipsen Pharma Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
RU2459831C2 (ru) * 2006-09-27 2012-08-27 Ипсен Фарма С.А.С. Аналоги грелина с замещением на n-конце
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
WO2011115871A1 (en) * 2010-03-15 2011-09-22 Ipsen Pharma S.A.S. Pharmaceutical compositions of growth hormone secretagogue receptor ligands
BR112014015275A2 (pt) 2011-12-23 2017-06-13 Ipsen Mfg Ireland Limited processo para a síntese de peptídeos terapêuticos

Also Published As

Publication number Publication date
WO2007041278A3 (en) 2007-10-04
EP3586846A1 (en) 2020-01-01
EP1937262A2 (en) 2008-07-02
SI1937262T1 (sl) 2019-09-30
WO2007041278B1 (en) 2007-12-06
CN101287464A (zh) 2008-10-15
RU2420305C2 (ru) 2011-06-10
EP1937262A4 (en) 2014-09-24
EP1937262B1 (en) 2019-05-08
CN105381453B9 (zh) 2019-01-11
CN105381453A (zh) 2016-03-09
US20150218245A1 (en) 2015-08-06
US8981054B2 (en) 2015-03-17
RU2566708C2 (ru) 2015-10-27
JP2015038116A (ja) 2015-02-26
CN105381453B (zh) 2018-11-13
PL1937262T3 (pl) 2019-10-31
HUE044391T2 (hu) 2019-10-28
US20200347110A1 (en) 2020-11-05
JP5230430B2 (ja) 2013-07-10
ES2740108T3 (es) 2020-02-05
JP2009510098A (ja) 2009-03-12
US20170037104A1 (en) 2017-02-09
CN103251933A (zh) 2013-08-21
US7932231B2 (en) 2011-04-26
CA2625447C (en) 2015-06-09
JP5960563B2 (ja) 2016-08-02
JP6419864B2 (ja) 2018-11-07
CA2625447A1 (en) 2007-04-12
RU2008116837A (ru) 2009-11-10
US20110166069A1 (en) 2011-07-07
PT1937262T (pt) 2019-08-21
RU2011103062A (ru) 2012-08-10
WO2007041278A2 (en) 2007-04-12
US20090304724A1 (en) 2009-12-10
US20190248861A1 (en) 2019-08-15
JP2017095494A (ja) 2017-06-01
US9499599B2 (en) 2016-11-22
DK1937262T3 (da) 2019-07-15
JP2013035856A (ja) 2013-02-21

Similar Documents

Publication Publication Date Title
CY1122134T1 (el) Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας
CY1124103T1 (el) Δοσολογικο σχημα που σχετιζεται με ενεσιμους εστερες παλιπεριδονης μακρας δρασης
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
DK1933833T3 (da) Terapi til behandling af overaktiv blære
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
BRPI0606587A2 (pt) uso de metilnaltrexona e compostos correlatos para tratar disfunção gastrintestinal pós-operatória
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
DE602005026556D1 (de) Zusammensetzung zur proteasomhemmung
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
WO2007087468A3 (en) Adiponectin for treatment of various disorders
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA201290322A1 (ru) Лечение желудочно-кишечных расстройств
EA201001639A1 (ru) Композиции и способы их получения и применения
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200870093A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения ожирения
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
CY1119819T1 (el) Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας
EA201891416A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
EA201200428A1 (ru) Композиция и способ для лечения ожирения
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden